# Central Nervous System(CNS) Efficacy of Dacomitinib

> **NCT04675008** · PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Brain Metastases

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04675008
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-07
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04675008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04675008, "Central Nervous System(CNS) Efficacy of Dacomitinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04675008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*